Abstract: A causal inference engine relies on a category database and a graph database. Via a loader, a category generator, and a spatial web generator, input data is received in disparate formats and converted into a normalized attribute vector comprising a mathematical model, experiment, experimental data, and miscellaneous attributes. The normalized attribute vectors are then loaded into a category database and a graph database. Specifically, the loader makes use of a multi-formal combinatorial parser, and an ontology store to convert the different data and formats into normalized attribute vectors. The category generator reviews mathematical model attributes in the normalized attribute vectors to associate vectors into mathematical categories. The spatial web generator performs similarity scores in the attributes of the vectors to determine placement in a graph database. The data in the category database and the graph database are then utilized by the causal inference engine to perform inferences.

Abstract: A causal inference engine makes inferences based on a vector of attributes in a standardized format called a normalized attribute vector. Candidate correlations between the normalized attribute vectors are made via a machine learning algorithm operating on the attributes of the normalized attribute vectors. The candidate correlations are then validated against a set of known mechanisms, in some cases selected by making use of mathematical category theory. Where a candidate correlation is shown to be similar to a mechanism, or composition of mechanisms, the candidate correlation is validated as being causative rather than just a correlation. Where causation can be shown to have a confidence above a predetermined threshold, the correlation is then stored as to be used to validate other correlations in future processing.

Abstract: A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.

Abstract: A method for treating patients in need of percutaneous transluminal coronary angioplasty which comprises administering nonionic contract media to the patient and treating the patient with a fibrinogen receptor antagonist.